Market research

Patient Blood Management

Explore licenses

Assess the study’s coverageRead the public overview, then compare the chapter outline with your research brief.

16report chapters

360iResearch introduction

Public research overview

Patient Blood Management: An Executive Overview

Patient blood management (PBM) is a coordinated, evidence-based approach to improving patient outcomes by managing anemia, reducing avoidable blood loss, and supporting appropriate transfusion decisions. It combines preoperative assessment, optimization of red-cell production, blood-conservation techniques, and individualized transfusion thresholds across the care pathway. PBM is relevant to surgery, trauma, oncology, obstetrics, critical care, and other settings where anemia and transfusion exposure can influence recovery, safety, and resource use.

Inside the research

Coverage at a glance

Selected branches from the published table of contents. Follow a chapter to see every subchapter in context.

  1. Chapter 7 Product Type

    • Antifibrinolytics
    • Autotransfusion Systems
    • Blood Component Separation Systems
    • Blood Management Disposables
    More in this chapter
  2. Chapter 8 Therapy Type

    • Allogeneic Transfusion
    • Autologous Transfusion
    • Cell Salvage
    • Hemostasis Management
    More in this chapter
  3. Chapter 9 Application

    • Cardiovascular Surgery
    • Elective Surgery
    • Obstetrics
    • Oncology Treatments
    More in this chapter

Clinical Practice Is Shifting Toward Patient-Centered Blood Stewardship

The landscape is moving from component-focused transfusion practice toward integrated stewardship of the patient’s own blood. Hospitals are strengthening preoperative anemia screening, investigating iron deficiency and other correctable causes, applying restrictive and context-specific transfusion protocols, and expanding perioperative conservation methods. Electronic decision support, multidisciplinary governance, audit programs, and standardized clinical pathways are helping translate guidelines into routine practice while preserving clinician judgment for complex cases.

Artificial Intelligence Is Strengthening Detection, Decision Support, and Learning Systems

Artificial intelligence can support PBM by identifying patients at risk of anemia or transfusion, prioritizing laboratory review, detecting changes in hemoglobin and blood-loss patterns, and helping clinicians apply locally approved protocols. Predictive tools may also improve scheduling of optimization interventions and support inventory-aware care coordination. Their value depends on representative training data, transparent validation, strong privacy controls, monitoring for bias, and human oversight; AI should complement rather than replace clinical assessment and shared decision-making.

Regional Insights: Adoption Reflects Health-System Capacity and Policy Maturity

North America is characterized by mature hospital governance, quality measurement, and technology adoption, while Latin America is emphasizing practical anemia management, blood-safety improvement, and scalable protocols amid uneven resources. Europe continues to benefit from coordinated clinical guidance and cross-border quality initiatives. The Middle East is expanding specialized hospital capacity and structured perioperative programs, while Africa’s priorities include reliable diagnostics, blood availability, maternal care, and adaptable low-resource pathways. Asia-Pacific presents diverse conditions, combining advanced PBM programs in developed systems with substantial opportunities to improve screening, conservation, and transfusion stewardship across rapidly expanding care networks.

Group Insights: Policy Alignment and Cross-Border Collaboration Shape Implementation

ASEAN countries face varied infrastructure and workforce conditions, making adaptable protocols, training, and regional knowledge exchange important. BRICS members span highly different health-system capabilities and can benefit from locally validated approaches to anemia diagnosis, blood conservation, and data governance. The European Union supports harmonization through shared standards and collaborative clinical learning. G7 systems generally have strong research, quality, and digital capabilities, but continue to focus on implementation consistency. GCC health systems are investing in advanced hospital services and coordinated perioperative care. NATO members may benefit from interoperability, trauma-readiness, and resilient blood-management planning, particularly for emergency and mass-casualty contexts.

Country Insights: National Priorities Vary Across Clinical and Operational Contexts

Australia has established experience with patient-centered transfusion stewardship and perioperative quality improvement. Brazil and Mexico are addressing access, anemia diagnosis, and consistency across diverse public and private settings. Canada, the United States, the United Kingdom, France, Germany, Italy, and Spain are advancing guideline-based PBM through hospital programs, audit, and multidisciplinary practice, with continued attention to variation between institutions. China and India are combining expanding clinical capacity with opportunities for broader screening, standardized pathways, and workforce development. Japan and South Korea bring strong hospital infrastructure and procedural expertise, while Russia’s priorities include maintaining reliable blood services, clinical protocols, and regional implementation capacity.

Leadership Priorities for Embedding Patient Blood Management

Industry leaders should establish executive ownership with measurable clinical objectives, beginning with routine screening and treatment of anemia before elective procedures. They should create multidisciplinary PBM teams, align transfusion policies with current evidence, and track indicators such as anemia identification, appropriate therapy, blood loss, transfusion appropriateness, and patient outcomes. Investment should favor interoperable laboratory and clinical data, validated decision support, workforce education, and equitable access to diagnostics and iron therapies. Partnerships with clinicians, patients, blood services, regulators, and technology teams can accelerate adoption while ensuring that AI-enabled tools remain auditable, explainable, secure, and clinically governed.

Research Methodology: Evidence-Based Synthesis of Clinical and System Drivers

This executive summary uses a structured, qualitative synthesis of established PBM principles, clinical practice patterns, health-system priorities, digital-health considerations, and regional implementation conditions. Analysis is organized across the care pathway, including anemia detection and treatment, blood-loss reduction, transfusion decision-making, governance, workforce capability, data infrastructure, and resilience. Regional, group, and country observations are framed as contextual insights rather than quantitative comparisons. No market estimates, forecasts, market shares, or company-specific claims are used.

Conclusion: PBM Connects Better Outcomes With Responsible Resource Stewardship

Patient blood management is increasingly recognized as a core element of safe, high-quality care rather than a narrow transfusion initiative. Its strongest results come from coordinated action before, during, and after procedures: detect and treat anemia, minimize avoidable blood loss, and transfuse only when clinically appropriate. Sustainable progress will depend on accountable leadership, practical pathways, reliable data, equitable implementation, and carefully governed digital and AI capabilities across diverse health systems.

Research report

Table of contents

  1. 1.Preface
    1. 1.1Objectives of the Study
    2. 1.2Market Definition
    3. 1.3Market Segmentation & Coverage
    4. 1.4Years Considered for the Study
    5. 1.5Currency Considered for the Study
    6. 1.6Language Considered for the Study
    7. 1.7Key Stakeholders
  2. 2.Research Methodology
    1. 2.1Introduction
    2. 2.2Research Design
      1. 2.2.1Primary Research
      2. 2.2.2Secondary Research
    3. 2.3Research Framework
      1. 2.3.1Qualitative Analysis
      2. 2.3.2Quantitative Analysis
    4. 2.4Market Size Estimation
      1. 2.4.1Top-Down Approach
      2. 2.4.2Bottom-Up Approach
    5. 2.5Data Triangulation
    6. 2.6Research Outcomes
    7. 2.7Research Assumptions
    8. 2.8Research Limitations
  3. 3.Executive Summary
    1. 3.1Introduction
    2. 3.2CXO Perspective
    3. 3.3New Revenue Opportunities
    4. 3.4Next-Generation Business Models
    5. 3.5Industry Roadmap
  4. 4.Market Overview
    1. 4.1Introduction
    2. 4.2Industry Ecosystem & Value Chain Analysis
      1. 4.2.1Supply-Side Analysis
      2. 4.2.2Demand-Side Analysis
      3. 4.2.3Stakeholder Analysis
    3. 4.3Market Dynamics
      1. 4.3.1Key Drivers
      2. 4.3.2Key Restraints
      3. 4.3.3Key Opportunities
      4. 4.3.4Key Challenges
    4. 4.4Porter’s Five Forces Analysis
    5. 4.5PESTLE Analysis
    6. 4.6Market Outlook
      1. 4.6.1Near-Term Market Outlook (0–2 Years)
      2. 4.6.2Medium-Term Market Outlook (3–5 Years)
      3. 4.6.3Long-Term Market Outlook (5–10 Years)
    7. 4.7Go-to-Market Strategy
  5. 5.Market Insights
    1. 5.1Consumer Insights & End-User Perspective
    2. 5.2Consumer Experience Benchmarking
    3. 5.3Opportunity Mapping
    4. 5.4Distribution Channel Analysis
    5. 5.5Pricing Trend Analysis
    6. 5.6Regulatory Compliance & Standards Framework
    7. 5.7ESG & Sustainability Analysis
    8. 5.8Disruption & Risk Scenarios
    9. 5.9Return on Investment & Cost-Benefit Analysis
  6. 6.Cumulative Impact of Artificial Intelligence 2026
  7. 7.Patient Blood Management Market, by Product Type
    1. 7.1Introduction
    2. 7.2Antifibrinolytics
    3. 7.3Autotransfusion Systems
    4. 7.4Blood Component Separation Systems
    5. 7.5Blood Management Disposables
      1. 7.5.1Cell Washing Kits
      2. 7.5.2Collection Reservoirs
      3. 7.5.3Filtration Devices
    6. 7.6Coagulation Monitoring Systems
      1. 7.6.1Laboratory Analyzers
      2. 7.6.2Point Of Care Devices
    7. 7.7Hemostats And Sealants
      1. 7.7.1Sealant Systems
      2. 7.7.2Topical Hemostats
    8. 7.8Volume Expanders
  8. 8.Patient Blood Management Market, by Therapy Type
    1. 8.1Introduction
    2. 8.2Allogeneic Transfusion
    3. 8.3Autologous Transfusion
    4. 8.4Cell Salvage
    5. 8.5Hemostasis Management
      1. 8.5.1Antifibrinolytic Therapy
      2. 8.5.2Topical Hemostats Therapy
    6. 8.6Perioperative Blood Conservation
      1. 8.6.1Intraoperative Techniques
      2. 8.6.2Postoperative Care
      3. 8.6.3Preoperative Optimization
  9. 9.Patient Blood Management Market, by Application
    1. 9.1Introduction
    2. 9.2Cardiovascular Surgery
      1. 9.2.1Aortic Surgery
      2. 9.2.2Coronary Artery Bypass Grafting
      3. 9.2.3Valve Replacement Procedures
    3. 9.3Elective Surgery
    4. 9.4Obstetrics
    5. 9.5Oncology Treatments
      1. 9.5.1Chemotherapy
      2. 9.5.2Radiotherapy
    6. 9.6Trauma
  10. 10.Patient Blood Management Market, by End User
    1. 10.1Introduction
    2. 10.2Ambulatory Surgical Centers
    3. 10.3Clinics
    4. 10.4Hospitals
    5. 10.5Specialty Centers
      1. 10.5.1Cancer Treatment Centers
      2. 10.5.2Cardiac Care Centers
      3. 10.5.3Trauma Centers
  11. 11.Patient Blood Management Market, by Region
    1. 11.1Introduction
    2. 11.2Asia-Pacific
    3. 11.3Europe
    4. 11.4North America
    5. 11.5Latin America
    6. 11.6Africa
    7. 11.7Middle East
  12. 12.Patient Blood Management Market, by Group
    1. 12.1Introduction
    2. 12.2NATO
    3. 12.3G7
    4. 12.4BRICS
    5. 12.5European Union
    6. 12.6ASEAN
    7. 12.7GCC
  13. 13.Patient Blood Management Market, by Country
    1. 13.1Introduction
    2. 13.2China
    3. 13.3United States
    4. 13.4Japan
    5. 13.5India
    6. 13.6Germany
    7. 13.7United Kingdom
    8. 13.8Australia
    9. 13.9France
    10. 13.10South Korea
    11. 13.11Italy
    12. 13.12Canada
    13. 13.13Russia
    14. 13.14Brazil
    15. 13.15Mexico
    16. 13.16Spain
  14. 14.Competitive Landscape
    1. 14.1Market Share Analysis, 2025
    2. 14.2Market Concentration Analysis, 2025
      1. 14.2.1Concentration Ratio (CR)
      2. 14.2.2Herfindahl Hirschman Index (HHI)
    3. 14.3Recent Developments & Impact Analysis, 2025
    4. 14.4Product Portfolio Analysis, 2025
    5. 14.5Benchmarking Analysis, 2025
  15. 15.Company Profiles
    1. 15.1Baxter International Inc.
    2. 15.2BioMérieux SA
    3. 15.3CSL Limited
    4. 15.4Danaher Corporation
    5. 15.5Fresenius Kabi AG
    6. 15.6Grifols, S.A.
    7. 15.7Haemonetics Corporation
    8. 15.8LivaNova PLC
    9. 15.9Macopharma SA
    10. 15.10Octapharma AG
    11. 15.11Roche Diagnostics International AG
    12. 15.12Terumo Corporation
    13. 15.13ZOLL Medical Corporation
  16. 16.Key Experts

Loading the sample request form…